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Background 
Description of the condition
Smoking is the world's leading cause of preventable illness and death (WHO 2011). One in every two smokers will die of
a smoking-related disease, unless they quit (Doll 2004; Pirie 2013). In high-income countries, the prevalence of
smoking has decreased markedly from the 1970s; for example, in the UK it has fallen from 46% to approximately 14.9%
Smoking cessation for improving mental health
1 / 10
in 2018 (ONS 2018; West 2019). However, smoking prevalence amongst people with mental illness has declined
only slightly and is currently around 32% (Richardson 2019; Szatkowski 2015; Taylor 2019). Smokers with mental
illness are more heavily addicted, suffer from worse withdrawal (Hitsman 2013; Leventhal 2013; Leventhal 2014; RCP/RC
PSYCH 2013), and are less responsive to standard treatments (Hitsman 2013; Taylor 2019), even though they are
motivated to quit (Haukkala 2000; Siru 2009). These inequalities contribute to a reduction in life expectancy of up to
17.5 years compared to the general population (Chang 2011; Chesney 2014).
Description of the intervention
Some smokers and healthcare providers believe that smoking can reduce stress and other symptoms related to
mental illness, and these beliefs maintain a culture of smoking in mental health settings (Cookson 2014; Sheals 2016).
However, our previously published review found a strong association between smoking cessation and improvements in
mental health that were equal to or larger than the effect of taking antidepressants (Taylor 2014). We argued that this was
likely to be causal, and that smoking cessation can lead to improved mental health.
How the intervention might work
Chronic tobacco smoking is associated with neuroadaptations in nicotinic pathways in the brain. Neuroadaptations
in these pathways are associated with the occurrence of withdrawal symptoms, such as depressed mood, agitation
and anxiety. Withdrawal symptoms are alleviated by smoking and remain alleviated shortly after smoking, but
symptoms return when blood levels of nicotine decline at around 20 minutes after smoking (Benowitz 1990; Benowitz 2010; 
Mansvelder 2002); this is known as the withdrawal cycle and is marked by fluctuations in a smoker's psychological
state throughout the day (Benowitz 2010; Parrott 2003). Therefore, smokers and non-smokers alike mistake the
ability of tobacco to alleviate tobacco withdrawal for an ability to alleviate mental health-related symptoms. This
misunderstanding has negative consequences in treating tobacco addiction in mental health populations, as many
healthcare providers believe that by helping their patients to quit smoking, they will be harming their patients' mental
health (Cookson 2014; Sheals 2016).
Recent observational studies have used methods that support strong causal inference, to indicate that smoking
increases the risk of depression and schizophrenia (Wootton 2018), and that smoking cessation leads to a reduction in
the prescription of antidepressants and anxiolytics (Taylor 2019). When inferring causal associations from epidemiological
studies, it is important to consider the strength of association, reverse causation, potential confounding, and biological
plausibility. To date, there is evidence that our hypothesis that smoking cessation improves mental health meets these
considerations.
Strength of association: the strength of the pooled association in our previous review, exploring the association
between smoking cessation and mental health (Taylor 2014), was clinically important - the association between smoking
cessation and change in depression and anxiety was equal to or larger than the estimate from trials of antidepressants
versus placebo. Fournier 2010 meta-analysed individual-level data from randomised controlled trials
(RCTs) (6 RCTs, N = 718) of selective serotonin reuptake inhibitors for "mild" to "severe" depression. The
resulting effect estimates ranged from standardised mean difference (SMD) -0.11, 95% confidence
interval (CI) - 0.26 to −0.04 to SMD -0.47, 95% CI –0.59 to -0.34 for change in depression. The effect
size for smoking cessation was SMD −0.25, 95% CI −0.37 to −0.12, which falls within this range (Taylor 2014
). A meta-analysis of 34 RCTs assessed the effect of antidepressants on generalised anxiety disorder (NCCMH 2011),
and effect estimates ranged from SMD −0.23, 95% CI −0.32 to −0.14 to SMD −0.50, 95% CI −0.77 to −0.23;
this is similar to the effect smoking cessation had on anxiety (SMD −0.37, 95% CI −0.70 to −0.03).
Reverse causation: one explanation for the association between smoking cessation and improvements in mental
health is that improved mental health prompts people to attempt cessation. However, over half of the studies in our
previous review were secondary analyses of RCTs (Taylor 2014). In these studies everyone attempted cessation,
and therefore the decision to quit was not contingent on change in mental health. Observed changes in mental
health were measured after entry into the trials. Subgroup analyses showed no difference between estimates that
were derived from RCTs and from population cohorts (in which reverse causation was more likely). Second, a
recent study employing mendelian randomisation, one of the strongest available causal methods in epidemiology,
also supports this relationship between smoking and mental health by providing evidence that smoking causes
mental illnesses, such as depression and schizophrenia (other mental illnesses were not examined) (Wootton 2018
). It could be that improved mental health predicts the likelihood of a successful quit attempt or that worsened
mental health after cessation predicts relapse. However, in our previous observational analysis of RCT data there
was no greater tendency to relapse at 12 months for those whose mental health worsened after cessation
compared with those who had no change or an improvement; odds ratio (OR) 1.01, 95% CI 0.97 to 1.05 (Taylor 2015).
Potential confounding: in our previous review, two studies supplying estimates for the change in three mental health
outcomes (i.e. anxiety, depression, and positive affect) provided effect sizes adjusted for confounders (Taylor 2014
). The confounders included demographics, tobacco consumption, and/or treatment allocation. Comparison of these
adjusted estimates with unadjusted estimates indicated no meaningful change in the results. Another study
triangulated evidence for the relative effect of varenicline compared to nicotine replacement therapy on mental
health outcomes (i.e. depression, anxiety, antidepressants and anxiolytics) (Taylor 2019). The study used three analytical
approaches, allowing for different levels of control for confounding: multivariable regression modelling (little control for
confounding), propensity score matched regression modelling (less susceptible to confounding), and instrumental variable
analysis (unlikely to be effected by confounding). All three models consistently found that varenicline was associated with
decreased odds of receiving mental health diagnoses and prescriptions, suggesting that no confounding factors were
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influencing the results.
Biological plausibility: the hypothesis that cessation improves mental health is supported by a plausible biological
mechanism, related to neuroadaptations in nicotinic pathways in the brain (Benowitz 2010), as previously
described. The constant fluctuation in withdrawal-induced psychological symptoms experienced by smokers could
worsen mental health over time, and the associated biological effects could increase the risk of mental illness (Parrott
2003; Wootton 2018). It is likely that after breaking the tobacco withdrawal cycle, through quitting smoking, these
systems recover (Mamede 2007), in the same way that other systems damaged by tobacco heal after cessation (Doll
2004; Pirie 2013). This is consistent with reports that withdrawal symptoms abate a few weeks after quitting
smoking (Hughes 2007).
Why it is important to do this review
There is little convincing evidence that the smoking epidemic amongst people with mental illness is subsiding to
the same level as observed in the general population - the gap in prevalence between smokers with and without
mental illness is not closing (Richardson 2019; Taylor 2019). Given evidence of therapeutic nihilism amongst
healthcare professionals (Sheals 2016), strengthening, communicating and updating the evidence exploring the association
between smoking and mental health is critically important to populations with mental illness. It could also encourage people
who smoke without mental illness to quit and discourage others from beginning to smoke tobacco.
Objectives 
To investigate the association between tobacco smoking cessation and subsequent mental health outcomes.
Methods 
Criteria for considering studies for this review 
Types of studies 
Controlled before-after studies, including randomised controlled trials (RCTs) analysed by smoking status. We will conduct
secondary analysis of RCTs and cohort studies to compare those who quit smoking with continuing smokers, rather than
compare the randomised study arms.
Types of participants 
Adult (using definitions given in included studies) tobacco smokers who continue or quit smoking; no restrictions by
population or comorbid conditions.
Types of interventions 
The intervention will be quitting smoking. We will include any definition of smoking cessation, as defined by the included
studies (i.e. self-report, bio-validated, point prevalence, continuous). We will prefer more stringent measures, and intention-
to-treat over complete case analysis where multiple definitions of quitting are reported.
Types of outcome measures 
Self-report or clinician scored measures of mental health. We will include continuous and dichotomous measures of mental
health, or mental ill-health.
Primary outcomes
Change in depression symptoms, at least six weeks follow-up from baseline
Change in anxiety symptoms, at least six weeks follow-up from baseline
Change in mixed anxiety and depression, at least six weeks follow-up from baseline
Secondary outcomes
Change in symptoms of stress, psychological quality of life, and positive affect
Mental ill-health, including measures of depression, anxiety, stress, psychological quality of life, positive effect, mixed
anxiety and depression
Social impact, including measures of social satisfaction, interpersonal relationships, isolation and loneliness. We
carried out patient and public involvement work to identify any outcomes of particular relevance to members of
the public, which were not considered in the previous version of this review (Fournier 2010 ). This work highlighted that
people who smoke may be concerned that quitting could disrupt their social networks, and lead to feelings of loneliness.
This may be of particular significance to people also experiencing mental ill-health.
Search methods for identification of studies 
Electronic searches 
We will search Cochrane Central Register of Controlled Trials, MEDLINE, Embase, PsycINFO, and the Cochrane
Tobacco Addiction Group's Specialised Register. The most recent searches of these databases for the previous non-
Cochrane version of this review were carried out on 13 April 2012 (Taylor 2014). The inclusion criteria specified in this
protocol do not differ from those in the original review, therefore we will include studies included in the previous review and
conduct updated searches from 14 April 2012 to present, to identify any new studies. See Appendix 1 for the MEDLINE
search strategy.
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Searching other resources 
We will search the reference lists of eligible studies, and the following trial databases: ClinicalTrials.gov
(www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP;
www.who.int/ictrp).
Data collection and analysis 
Selection of studies 
Our aim will be to maximise sensitivity by including studies in initial screens even if data directly relevant to our question are
not presented in the abstract. The titles and abstracts of eligible titles will be screened by two review authors (GT, NL, AF)
independently for inclusion. If there are disagreements these will be resolved by discussion and a third review author will be
involved where necessary. We will obtain the full-text of any articles that are included at the title and abstract screening
stage. Each full-text will be screened by two review authors (GT, NL, AF) independently for inclusion. If there are
disagreements these will be resolved by discussion and a third review author will be involved where necessary. Reasons for
exclusion at the full-text examination stage will be recorded. We will translate all non-English language studies.
Data extraction and management 
Two review authors will pilot the data extraction form and make appropriate changes (GT, NL).
Two review authors (two of GT, NL, AF) will in duplicate extract data independently for each study. These will be compared
for each study and any disagreements will be resolved by discussion and a third review author will be involved where
necessary.
We will extract the following data from each study.
Study design
Analysis method
Outcome measure(s)
Length of follow-up
N at baseline and follow-up
Population type
Percentage (%) male
Mean age (standard deviation (SD))
Covariates adjusted for
Motivation to quit
Intervention(s) used (if relevant)
Risk of bias using ROBINS-I (Sterne 2016)
Data to calculate standardised mean difference (SMD) in mental health outcomes: for each group - mean at baseline and
follow-up, mean change from baseline to follow-up, and difference in mean change from baseline to follow-up, and
variance
Data to calculate risk of mental ill-health outcomes: for each group - N participants in the control group at baseline, N
participants in exposure group at baseline, N participants with mental ill-health in the exposure group at follow-up, N
participants with mental ill-health in the control group at follow-up
Sources of study funding and authors' declarations of interests
Assessment of risk of bias in included studies
We will assess the risk of bias for each non-randomised study, and each RCT (analysed according to smoking
cessation status rather than by trial arm) using ROBINS-I, which assesses studies based on risk of bias in the
following domains: bias due to confounding, bias in selection of participants into the study, bias in classification of
interventions, bias due to deviations from intended interventions, bias in measurement of outcomes, and bias in
selection of the reported result (Sterne 2016).
Measures of treatment effect
SMD in change in mental health from baseline to follow-up, between those who have quit smoking and those who
continue to smoke for each study. We will calculate the SMD and its variance by extracting data in order of
preference for meta-analysis: 1) adjusted or unadjusted SMD (difference in change from baseline to follow-up) and
measure of variation between exposure groups (preference for adjusted estimates), 2) mean change in mental
health scores from baseline to follow-up and measure of variance, by exposure group, 3) mean mental health
scores and measures of variance at baseline and final follow-up, by exposure group. Then using a standard formula
we will calculate the mean change and it's variance by exposure group (Follmann 1992), and then the SMD, using standard
formulae outlined within the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Risk ratio (RR) and 95% confidence interval (CI) for mental ill-health: we will extract data to calculate the RR for mental ill-
health and its variance for each study using the following formula: (number of participants with mental ill-health in the
exposure group/number of participants in exposure group at baseline) divided by (number of participants with mental ill-
health in the control group/number of participants in the control group at baseline).
Unit of analysis issues 
We do not foresee any analysis issues.
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Dealing with missing data
We will contact the corresponding authors of studies for additional data where necessary. We will report studies narratively if
we cannot obtain outcome data.
Assessment of heterogeneity 
We will investigate whether there appears to be any clinical or methodological heterogeneity between studies before
pooling to establish whether it is appropriate to carry out meta-analysis. Where pooling does take place we will quantify
statistical heterogeneity using I2, which describes the percentage (%) of between-study variability due to heterogeneity
rather than chance. We will consider an I2 value between 50% and 75% as substantial heterogeneity, and above 75% we will
assess whether it is appropriate to report a pooled analysis.
Assessment of reporting biases
We will examine funnel plots for evidence of asymmetry and conduct Egger tests for evidence of small study bias where
there are 10 or more studies contributing to a comparison.
Data synthesis
We will pool the SMDs in change and measures of variance of individual studies using a generic inverse variance random-
effects model. A SMD of greater than zero will indicate that quitting smoking is associated with worse mental health at follow-
up.
We will pool risk ratios (RRs) and pool measures of variance calculated for individual studies using a Mantel-Haenszel
random-effects meta-analysis. A RR of greater than one will indicate that people who quit smoking experience a greater risk
of mental ill-health at follow-up.
We will conduct meta-analyses of the SMD and RR for each outcome separately (i.e. depression, anxiety, stress, etc.) using
RevMan 2014.
Subgroup analysis and investigation of heterogeneity 
Adjustment for covariates: we will compare effect estimates from studies that present adjusted and unadjusted estimates.
Motivation to quit: we will classify studies according to whether they selected participants for inclusion based on motivation to
quit (i.e. participants in RCTs will be classed as motivated to quit assuming that participants enrolled in a trial to help them
stop smoking). We will compare estimates resulting from these studies, and cohort studies that follow a group of people who
smoke, where the majority are likely not to want to quit in the near future. If we find any studies that adjusted effect estimates
for motivation to quit we will compare unadjusted and adjusted estimates.
Study design: we will compare estimates between secondary analyses of trials, classic cohort studies, and cohort studies
adopting causal designs (e.g. propensity score matching, or instrumental variable analyses).
Population comparison: we will examine whether there is evidence of a difference in effect size between studies in different
clinical populations (e.g. pregnancy, mental disorder, post-surgical) and the general population. This is important for those
with mental disorders in particular, because poor implementation of smoking cessation interventions for people with mental
illness is supported by the belief that stopping smoking will worsen their mental health.
Length of follow-up: we will examine whether there is evidence of a difference in effect estimate between studies that
assessed mental health between baseline and six weeks (i.e. to ensure follow-up occurs after the acute tobacco withdrawal
period), and studies that assessed to six months or more than six months. This may differ because people who achieve a
difficult life goal may have a temporary improvement in mental health because of their achievement. However, should the
effect persist long-term, this supports the hypothesis that smoking itself is harmful to mental health and it is ceasing smoking
and not the celebration of that achievement that improves mood.
Sensitivity analysis
Loss to follow-up: we will conduct a sensitivity analysis with removal of studies in which different numbers of participants
were analysed at baseline and follow-up.
Ascertainment of smoking status: we will conduct a sensitivity analysis with removal of studies that did not biochemically
verify smoking status.
Psychotherapeutic/psychoactive component within cessation intervention: we will conduct a sensitivity analysis with removal
of studies that offered a psychotherapeutic/psychoactive (i.e. psychotherapy or antidepressants) component within the
smoking cessation intervention.
Risk of bias: We will conduct a sensitivity analysis removing studies that are at a high risk of bias.
'Summary of findings' table and GRADE
We will create a 'Summary of findings' table, using GRADEpro GDT software, reporting the pooled effect
estimates for our primary outcomes and the social impact outcome. We will assess these outcomes according
to the five GRADE considerations (Schünemann 2013; i.e. study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the certainty of the body of evidence for these outcomes, and to draw conclusions about the
certainty of the evidence within the text of the review.
Results 
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Appendices 
1 MEDLINE search strategy
1. exp "Tobacco Use Cessation"/ or exp Smoking Cessation/
2. smoking cessation.mp.
3. ((reduc* or modif*) adj3 (smok* or cigar* or tobacco)).mp.
4. ((quit* or stop* or give* or cease) adj3 (smok* or cigar* or tobacco)).mp.
5. Harm Reduction/ or harm reduction.mp.
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6. Smoking Reduction/
7. tobacco consumption.mp.
8. cold turkey.mp.
9. Smoking Cessation Agents/
10. "Tobacco Use Cessation Devices"/
11. Electronic Nicotine Delivery Systems/
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. Mental Health/ or mental health.mp.
14. Stress, Psychological/
15. psychological health.mp.
16. Resilience, Psychological/ or psychological resilience.mp.
17. Anxiety/ or anxiety.mp. or Anxiety Disorders/
18. anxious.mp.
19. Depression/ or depression.mp.
20. Depressive Disorders/ or depressive.mp.
21. Emotions/ or emotion*.mp.
22. psychological process$.mp.
23. mental hygiene.mp.
24. "Quality of Life"/ or quality of life.mp.
25. (well being or well?being).mp.
26. Affect/ or affect.mp. or Affective Symptoms/
27. Adaptation, Psychological/
28. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. 12 and 28
30. limit 29 to yr="2011 -Current"
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